AKT1 and melanoma: SRF/MRTF inhibitors could present an attractive approach to tackling BRAF inhibitor resistance in melanoma caused by RAC1P29S compared with the use of RAC inhibitors, which have to date proved difficult to progress into the clinic (Marei and Malliri, 2017).